Renal Impairment After Cardiac Surgery Clinical Trial
Official title:
Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery
The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.
All patients will receive standard supportive care based on current established management
practice of cardio-thoracic patients. The only difference in treatment will be the
randomisation of patients to receive/not receive protocolised administration of frusemide
targeting a urine output.
There will be 2 groups of patients. The control group-which will receive frusemide bolus
doses if required as determined by the surgeon/consultant physician. The frusemide infusion
group-which will be monitored to achieve a trial specified hourly urine output target range
of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading
dose of frusemide and may also then require a frusemide infusion. The aim will be to
maintain the urine output within the target range for the first 48 hours after cardiac
surgery.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention